Results 11 to 20 of about 595 (184)

A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient

Cell Death Discovery, 2023
Triple-negative breast cancer (TNBC) is the most aggressive subtype of mammary carcinoma. Here, we describe a case of an 81-year-old female diagnosed with ductal triple negative breast cancer with a germline pathogenic variant in BReast CAncer gene2 ...
Yuyi Han, Valentina Rovella, Artem Smirnov, Oreste Claudio Buonomo, Alessandro Mauriello, Tommaso Perretta, Yufang Shi, Jonathan Woodmsith, Julia Bischof, TOR CENTRE, Gerry Melino, Eleonora Candi, Francesca Bernassola   +12 more
doaj   +1 more source

Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?

Translational Oncology, 2020
Programmed cell death-ligand 2 (PD-L2) is one of the two ligands of the programmed cell death-1 (PD-1) receptor, an inhibitory protein mainly expressed on activated immune cells that is targeted in the clinic, with successful and remarkable results.
Cinzia Solinas, Marco Aiello, Esdy Rozali, Matteo Lambertini, Karen Willard-Gallo, Edoardo Migliori   +5 more
doaj   +1 more source

T follicular helper cells: linking cancer immunotherapy and immune-related adverse events

Journal for ImmunoTherapy of Cancer, 2021
Cancer immunotherapy utilizing immune checkpoint inhibitors (ICIs) has revolutionized the treatment of numerous cancer types. As the underlying mechanism of these treatments lies in the interference with inhibitory signals that usually impair potent ...
Dirk Baumjohann, Peter Brossart
doaj   +1 more source

Immunohistochemical Expression of Programmed Death Ligand-1 in Tumour Milieu of Oral Cancer

Annals of Abbasi Shaheed Hospital and Karachi Medical & Dental College, 2020
Objectives: To determine the immunohistochemical expression of PD-L1 in oral squamous cell carcinoma and to correlate it with clinicopathological parameters.
Moomal Aslam Khan, Serajuddaula Syed, Noor Ul Wahab, Saima Akram Butt   +3 more
doaj   +1 more source

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study

JTO Clinical and Research Reports, 2021
Introduction: We examined the long-term efficacy and safety of nivolumab, a human monoclonal antibody that inhibits interactions between the programmed cell death protein-1 receptor and its ligands (programmed death-ligand 1 and programmed death-ligand 2)
Nobukazu Fujimoto, MD, PhD, Morihito Okada, MD, PhD, Takashi Kijima, MD, PhD, Keisuke Aoe, MD, PhD, Terufumi Kato, MD, Kazuhiko Nakagawa, MD, PhD, Yuichiro Takeda, MD, PhD, Toyoaki Hida, MD, PhD, Kuninobu Kanai, MD, PhD, Jun Hirano, MPharm, Yuichiro Ohe, MD, PhD   +10 more
doaj   +1 more source

Identification ACTA2 and KDR as key proteins for prognosis of PD‐1/PD‐L1 blockade therapy in melanoma

Animal Models and Experimental Medicine, 2021
Programmed cell death protein 1 (PD‐1) /programmed cell death ligand 1 (PD‐L1) blockade is an important therapeutic strategy for melanoma, despite its low clinical response.
Yuchen Wang, Zhaojun Li, Zhihui Zhang, Xiaoguang Chen   +3 more
doaj   +1 more source

Design, Synthesis, Evaluation, and Structural Studies of C₂-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction

Journal of Medicinal Chemistry, 2019
A series of C2-symmetric inhibitors was designed and evaluated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (PPI) in a homogenous time-resolved fluorescence (HTRF) assay and PD-1 signaling in cell-based coculture assays.
Subhadwip Basu, Jeffrey Yang, Bin Xu, Katarzyna Magiera-Mularz, Lukasz Skalniak, Bogdan Musielak, Vladyslav Kholodovych, Tad A. Holak, Longqin Hu   +8 more
openaire   +3 more sources

Porphyromonas gingivalis Cell Wall Components Induce Programmed Death Ligand 1 (PD-L1) Expression on Human Oral Carcinoma Cells by a Receptor-Interacting Protein Kinase 2 (RIP2)-Dependent Mechanism

Infection and Immunity, 2020
Programmed death-ligand 1 (PD-L1/B7-H1) serves as a cosignaling molecule in cell-mediated immune responses and contributes to chronicity of inflammation and the escape of tumor cells from immunosurveillance. Here, we investigated the molecular mechanisms leading to PD-L1 upregulation in human oral carcinoma cells and in primary human ...
S, Groeger, F, Denter, G, Lochnit, M L, Schmitz, J, Meyle   +4 more
openaire   +3 more sources

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1

Chinese Medical Journal, 2020
. Historically, breast cancer has been regarded as an immunogenic “cold” tumor. However, the discovery of immune checkpoint inhibitors has made immunotherapy becoming an emerging new treatment modality for breast cancer.
Jing Zhao, Jian Huang, Qiang Shi
doaj   +1 more source

Immune checkpoint inhibitor‐induced asthma and chronic obstructive pulmonary disease overlap in patient with adenocarcinoma

Respirology Case Reports, 2023
A 67‐year‐old current smoker Japanese man, with no history of asthma, was diagnosed with lung adenocarcinoma. He received first‐line chemotherapy with carboplatin, pemetrexed, ipilimumab, and nivolumab in July 20XX‐1, and subsequently a maintenance ...
Yuki Hayakawa, Takako Kawaguchi, Kei Yamasaki, Miyu Endo, Masaya Komatsu, Yutaka Ishiguro, Yuichi Murata, Kazuhiro Yatera   +7 more
doaj   +1 more source